Clinical [qlco]
Efficacy [qlco]
sitaxsentan [orch, phsu]
Endothelin receptor antagonist [phsu]
In [qnco]
Patients [podg]
Pulmonary arterial hypertension [dsyn]
OPEN LABEL [resa]
Pilot [prog]
Study [mnob]
Study Objective [idcn]
To [qlco]
Evaluate [ftcn]
Safety [hcpp]
Efficacy [qlco]
sitaxsentan [orch, phsu]
Endothelin receptor antagonist [phsu]
OPEN LABEL [resa]
Trial [resa]
Of [spco]
Patients [podg]
Pulmonary arterial hypertension [dsyn]
Patients [podg]
Six [qnco]
Children [aggp]
Adults [aggp]
New York Heart Association Class II [fndg]
Functional [ftcn]
III [inpr]
Primary pulmonary hypertension [dsyn]
Patients [podg]
Pulmonary arterial hypertension [dsyn]
Associated [qlco]
congenital [qlco]
Systemic [ftcn]
pulmonary [bpoc]
Shunt [medd]
Collagen (vascular) disease NOS [dsyn]
measurements [ftcn]
sitaxsentan [orch, phsu]
Administered [ftcn]
Orally [spco]
mg% [qnco]
weeks [tmco]
Cardiopulmonary [blor]
Hemodynamics [ortf]
Cardiac Catheterization [diap, topp]
Obtained [ftcn]
baseline [bodm]
Distance [qnco]
Measured [qlco]
baseline [bodm]
Result [ftcn]
sitaxsentan [orch, phsu]
treatment [ftcn]
Result [ftcn]
Improvement [cnce]
Exercise [dora]
Capacity [qnco]
Assessed [acty]
Walk distance [fndg]
baseline [bodm]
Mean [qnco]
SD [fndg]
M NOS [aapp, imft]
M NOS [aapp, imft]
N NOS [aapp, imft]
P NOS [aapp, imft]
Mean [qnco]
Pulmonary artery pressure [lbtr]
Pulmonary vascular resistance index [orga]
Improved [qlco]
mmHg [qnco]
N NOS [aapp, imft]
P NOS [aapp, imft]
M NOS [aapp, imft]
N NOS [aapp, imft]
P NOS [aapp, imft]
Serious Adverse Event [fndg]
included [ftcn]
Two [qnco]
Cases [ftcn]
Acute hepatitis [dsyn]
Fatal [qlco]
One [qnco]
Conclusions [idcn]
Patients [podg]
New York Heart Association Class II [fndg]
Functional [ftcn]
III [inpr]
Patients [podg]
Pulmonary arterial hypertension [dsyn]
Show [inpr]
Improvement [cnce]
Exercise [dora]
Capacity [qnco]
Cardiopulmonary [blor]
Hemodynamics [ortf]
treatment [ftcn]
sitaxsentan [orch, phsu]
Endothelin receptor antagonist [phsu]
Further [spco]
Investigation [hlca]
To [qlco]
Evaluate [ftcn]
Safety [hcpp]
Efficacy [qlco]
sitaxsentan [orch, phsu]
Patients [podg]
With [qlco]
Patients [podg]
Pulmonary arterial hypertension [dsyn]
